GlassScriptPhysician profile
Stacy Ann Ignowski
NPI 1992363311
$1,822.80
in general payments reported to CMS, 2019-2025
24 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $244 · 2024: $654 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $309.44 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $280.30 | 2023-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $240.39 | 2024-2025 | |
| Lilly USA, LLC | $166.44 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $135.01 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.39 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $73.99 | 2023-2025 | Gemtesa |
| Abbvie INC. | $68.54 | 2023-2025 | |
| Cranial Technologies, INC | $54.70 | 2025 | Doc Band |
| Dexcom, INC. | $51.18 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $49.64 | 2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $46.65 | 2024-2025 | Shingrix, Bexsero, Penmenvy |
| Medtronic, INC. | $38.45 | 2025 | Intellis Adaptivestim, Minimed 780g |
| Nevro Corp. | $30.91 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $30.45 | 2025 | Enflonsia, Gardasil 9, Vaxneuvance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.96 | 2024 | Xifaxan, Trulance |
| Abbott Laboratories | $24.43 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $20.21 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $19.87 | 2023 | Xarelto |
| Mylan Specialty L.P. | $17.23 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $15.75 | 2025 | Symbravo |
| Novartis Pharmaceuticals Corporation | $15.71 | 2024 | |
| Seqirus USA INC | $15.28 | 2025 | Flucelvax |
| Kowa Pharmaceuticals America, INC. | $13.88 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Ignowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.